Characterization and aerodynamic evaluation of spray dried recombinant human growth hormone using protein stabilizing agents

被引:24
作者
Jalalipour, Monireh [1 ,2 ]
Gilani, Kambiz [1 ]
Tajerzadeh, Hosnieh [2 ]
Najafabadi, Abdolhossien Rouholamini [1 ,3 ]
Barghi, Mohammadali [4 ]
机构
[1] Univ Tehran Med Sci, Aerosol Res Lab, Sch Pharm, Tehran, Iran
[2] Univ Tehran Med Sci, Biopharm & Pharmacokinet Res Lab, Sch Pharm, Tehran, Iran
[3] Inst Pasteur, Nanobiotechnol Dept, Tehran, Iran
[4] Univ Tehran, XRD Res Lab, Sch Sci, Tehran, Iran
关键词
spray drying; dry powder inhaler; fine particle fraction; recombinant human growth hormone; protein stabilizers;
D O I
10.1016/j.ijpharm.2007.10.053
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effect of the protein stabilizers on the stability and aerosol performance of spray dried recombinant human growth hormone (SD rhGH) was investigated. rhGH solution was spray dried alone, with polysorbate 20 (at three concentrations of 0.05%, 0.01%, and 0.005%), Zn2+ (by Zn2+:rhGH molar ratio of 2:1 and 4:1), and/or lactose (by lactose:rhGH weight ratio of 2:1). Size exclusion chromatography (SEC) analysis of spray dried powders demonstrated that of all the potential protein stabilizers, the combination of polysorbate 20 (0.05%), Zn2+ (Zn2+:rhGH molar ratio of 2:1) and lactose (lactose:rhGH weight ratio of 2:1) was the most effective at protecting rhGH against aggregation during spray drying. The results of circular dichroism (CD) analysis revealed that using of polysorbate 20 (in all concentrations) and Zn2+ (by Zn2+:rhGH molar ratio of 2:1) together in the formulations would preserve rhGH conformational stability during the process. The particle size distribution data obtained by laser diffraction method showed all SD rhGH formulations had volume median diameter and mean diameter below 5 mu m. The characterization of the aerosol performance of the spray dried powders by Andersen cascade impactor (ACI) showed that by increasing the concentration of polysorbate 20 in the formulations the aerodynamic efficiency of the resultant particles was reduced. In conclusion, the optimum amounts of polysorbate 20, Zn2+ and lactose satisfied both physical stability during spray drying process (2.37% aggregation) and good aerosol performance (fine particle fraction; FPF = 38.52%). (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:209 / 216
页数:8
相关论文
共 31 条
[1]  
Adjei A.L, 1997, INHALATION DELIVERY, pxiii
[2]  
ALDER M, 1999, J PHARM SCI, V88, P199
[3]   Tween protects recombinant human growth hormone against agitation-induced damage via hydrophobic interactions [J].
Bam, NB ;
Cleland, JL ;
Yang, J ;
Manning, MC ;
Carpenter, JF ;
Kelley, RF ;
Randolph, JW .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (12) :1554-1559
[4]   CHEMICAL, PHYSICAL, AND BIOLOGICAL CHARACTERIZATION OF A DIMERIC FORM OF BIOSYNTHETIC HUMAN GROWTH-HORMONE [J].
BECKER, GW ;
BOWSHER, RR ;
MACKELLAR, WC ;
POOR, ML ;
TACKITT, PM ;
RIGGIN, RM .
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, 1987, 9 (06) :478-487
[5]   THE EFFECT OF PROCESS AND FORMULATION VARIABLES ON THE PROPERTIES OF SPRAY-DRIED BETA-GALACTOSIDASE [J].
BROADHEAD, J ;
ROUAN, SKE ;
HAU, I ;
RHODES, CT .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1994, 46 (06) :458-467
[6]   Use of solid corrugated particles to enhance powder aerosol performance [J].
Chew, NYK ;
Chan, HK .
PHARMACEUTICAL RESEARCH, 2001, 18 (11) :1570-1577
[7]   DIMERIZATION OF HUMAN GROWTH-HORMONE BY ZINC [J].
CUNNINGHAM, BC ;
MULKERRIN, MG ;
WELLS, JA .
SCIENCE, 1991, 253 (5019) :545-548
[8]   The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation [J].
French, DL ;
Edwards, DA ;
Niven, RW .
JOURNAL OF AEROSOL SCIENCE, 1996, 27 (05) :769-783
[9]   Characterization and in vivo study of sustained-release formulation of human growth hormone using sodium hyaluronate [J].
Hahn, SK ;
Kim, SJ ;
Kim, MJ ;
Kim, DH .
PHARMACEUTICAL RESEARCH, 2004, 21 (08) :1374-1381
[10]   EFFECT OF SURFACTANTS ON THE PHYSICAL STABILITY OF RECOMBINANT HUMAN GROWTH-HORMONE [J].
KATAKAM, M ;
BELL, LN ;
BANGA, AK .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 84 (06) :713-716